Cephalon/Alkermes Vivitrex User Fee Date Extended
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has extended the user fee date for Cephalon's and Alkermes' alcohol dependency therapy Vivitrex (naltrexone) by three months to Dec. 30, the companies announced Sept. 20